Cargando…
Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras
Lung cancer is the most malignant tumor in the worldwide. About 3%‐5% non‐small cell lung cancer (NSCLC) patients carry anaplastic lymphoma kinase (ALK) gene fusions and receive great benefits from ALK‐targeted therapy. However, drug resistance inevitably occurs even with the most potent inhibitor d...
Autores principales: | Song, Xiaoling, Zhong, Hui, Qu, Xiaojuan, Yang, Linsong, Jiang, Biao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554663/ https://www.ncbi.nlm.nih.gov/pubmed/34766150 http://dx.doi.org/10.1002/mco2.42 |
Ejemplares similares
-
Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022) -
Novel Design Strategies
to Enhance the Efficiency
of Proteolysis Targeting Chimeras
por: Zhao, Chunlong, et al.
Publicado: (2022) -
Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva‐Derived Endothelial Cells
por: Sánchez‐Duffhues, Gonzalo, et al.
Publicado: (2019) -
Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
por: de Klerk, Daniel J., et al.
Publicado: (2018) -
Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
por: Tamatam, Rekha, et al.
Publicado: (2023)